Seagull Technology utilises the electrical properties of polymers combined with ultrasonic stimulation to facilitate the release in regulated doses and subsequent movement of packaged or raw drugs across biological membranes.
The technology has been proven to be effective using a range of drugs in a rabbit eye model. Studies to date have shown that drugs ranging in size from larger proteins to small molecules can be successfully delivered to the back of the eye. These drugs are used to treat diseases such as Macular Degeneration and retinal conditions associated with Diabetic Eye Disease.
The core Intellectual Property is protected by patent applications, trademarks and company know-how.
With an active research and development program, Seagull Technology will continue to protect new Intellectual Property as it is generated both in-house and in conjunction with its industry partners.
